New shot targets hepatitis b cure in Asia-Pacific trial

NCT ID NCT07370207

Summary

This study is testing whether an experimental injection called AHB-137 can help control chronic hepatitis B in people already taking standard antiviral medications. Researchers will give the injection to 84 adults in Asia Pacific who have a specific type of hepatitis B and measure whether it reduces virus levels enough to potentially stop all treatment. The main goal is to see if participants achieve very low or undetectable virus levels after receiving AHB-137.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Chiayi Christian Hospital

    Chiayi City, 60002, Taiwan

  • E-DA Hospital

    Kaohsiung City, 82445, Taiwan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • National University Hospital - Singapore

    Singapore, 119074, Singapore

  • New Zealand Clinical Research

    Grafton, Auckland, 1010, New Zealand

  • Queen Mary Hospital - PPDS

    Hong Kong, China

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

Conditions

Explore the condition pages connected to this study.